Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 5, 2024

Study Completion Date

March 5, 2026

Conditions

Mesotheliomas Pleural

Interventions

DRUG

Pembrolizumab

Infusion

DRUG

Lenvatinib

Capsule

Trial Locations (1)

Antoni van Leeuwenhoekziekenhuis (NKI-AVL), Amsterdam

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT04287829 - Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients | Biotech Hunter | Biotech Hunter